1. Home
  2. AKBA vs LAW Comparison

AKBA vs LAW Comparison

Compare AKBA & LAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

N/A

Current Price

$0.57

Market Cap

248.3M

Sector

Health Care

ML Signal

N/A

Logo CS Disco Inc.

LAW

CS Disco Inc.

N/A

Current Price

$6.06

Market Cap

286.9M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
AKBA
LAW
Founded
2007
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
248.3M
286.9M
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
AKBA
LAW
Price
$0.57
$6.06
Analyst Decision
Buy
Buy
Analyst Count
6
3
Target Price
$3.25
★ $8.00
AVG Volume (30 Days)
★ 9.5M
236.0K
Earning Date
11-05-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 93.94
22.58
EPS
★ N/A
N/A
Revenue
N/A
★ $156,849,000.00
Revenue This Year
N/A
$12.74
Revenue Next Year
N/A
$10.55
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 8.29
52 Week Low
$0.36
$2.45
52 Week High
$1.84
$9.11

Technical Indicators

Market Signals
Indicator
AKBA
LAW
Relative Strength Index (RSI) 41.52 77.10
Support Level $0.54 $3.93
Resistance Level $1.00 $6.39
Average True Range (ATR) 0.07 0.29
MACD -0.01 0.05
Stochastic Oscillator 45.81 71.57

Price Performance

Historical Comparison
AKBA
LAW

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

About LAW CS Disco Inc.

CS Disco Inc provides a cloud-native, artificial intelligence-powered legal solution that simplifies discovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments. Its revenue-generating activities directly relate to the sale and support of legal solutions. It has two primary types of contractual arrangements: usage-based and subscription solutions. The usage-based revenue is derived from contracts under which customers are billed monthly based on their usage. Subscription revenue is derived from contracts where customers are contractually committed to a minimum data volume over a period of time.

Share on Social Networks: